drugset / Trial / NCT04679480
Anti-PD1-antibody and Pulsed HHI for Advanced BCC
Phase 2
Active not recruiting
20 enrolled
Reinhard Dummer
Sanofi · collabSun Pharmaceutical Industries, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the tumour response, safety and induction of immune response in patients with advanced BCC treated with a combination of anti-PD1 antibody and pulsed hedgehog inhibitor.
Timeline
- Start
- 2021-02-18
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Sonidegib | Small molecule | 200 mg | Oral |